Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 3/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | TK1 | P04183 | 4/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | TK2 | O00142 | 5/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9357958 | 0.77 | TYMP (0.44) | TYMPMAPK1TK1HPGDALDH1A1 | |
| SCHEMBL12862593 | 0.76 | TYMP (0.60) | TYMPMAPK1TK1HPGDALDH1A1 | |
| SCHEMBL17013817 | 0.76 | TYMP (0.60) | TYMPMAPK1TK1HPGDALDH1A1 | |
| SCHEMBL19181080 | 0.75 | TYMP (0.52) | TYMPMAPK1TK1HPGDTK2 | |
| SCHEMBL27054016 | 0.74 | TYMP (0.52) | TYMPMAPK1TK1HPGDTK2 | |
| SCHEMBL27054014 | 0.74 | TYMP (0.52) | TYMPMAPK1TK1HPGDTK2 | |
| SCHEMBL27058314 | 0.74 | TYMP (0.52) | TYMPMAPK1TK1HPGDTK2 | |
| SCHEMBL14944874 | 0.73 | TYMP (0.57) | TYMPMAPK1TK1HPGD | |
| SCHEMBL9353951 | 0.73 | TYMP (0.42) | TYMPMAPK1TK1HPGDALDH1A1 | |
| SCHEMBL24664443 | 0.72 | TYMP (0.56) | TYMPMAPK1TK1HPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10167302-B2 | Phosphonate nucleosides useful in the treatment of viral diseases | UNIVERSITY COLLEGE CORK (IE) | 2019-01-01 | — | — | US | disclosed |
| US-20170218001-A1 | PHOSPHONATE NUCLEOSIDES USEFUL IN THE TREATMENT OF VIRAL DISEASES | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2017-08-03 | — | — | US | disclosed |
| EP-3145939-A1 | PHOSPHONATE NUCLEOSIDES USEFUL IN THE TREATMENT OF VIRAL DISEASES | University College Cork (IE) | 2017-03-29 | — | — | EP | disclosed |
| WO-2015177351-A1 | PHOSPHONATE NUCLEOSIDES USEFUL IN THE TREATMENT OF VIRAL DISEASES | UNIVERSITY COLLEGE CORK (IE) | 2015-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10167302-B2 | Phosphonate nucleosides useful in the treatment of viral diseases | NR3C1, NR2E3, NR2E1 | TYMP 362/4885MAPK1 1953/4885TK1 106/4885 |
| US-20170218001-A1 | PHOSPHONATE NUCLEOSIDES USEFUL IN THE TREATMENT OF VIRAL DISEASES | NR3C1, NR2E3, NR2E1 | TYMP 362/4885MAPK1 1953/4885TK1 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.